<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7229548</article-id><article-id pub-id-type="doi">10.1155/2020/2824984</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tenacissoside H Induces Apoptosis and Inhibits Migration of Colon Cancer Cells by Downregulating Expression of <italic>GOLPH3</italic> Gene</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1190-6839</contrib-id><name><surname>Hong</surname><given-names>Zhong-Shi</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1500-6881</contrib-id><name><surname>Zhuang</surname><given-names>Hai-Bin</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5228-9104</contrib-id><name><surname>Qiu</surname><given-names>Cheng-Zhi</given-names></name><email>qchengzhi@fjmu.edu.cn</email><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6725-7017</contrib-id><name><surname>Shi</surname><given-names>Ze-Sheng</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5914-1447</contrib-id><name><surname>Wang</surname><given-names>Chun-Xiao</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3424-4009</contrib-id><name><surname>Chen</surname><given-names>Zhi-chuan</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Jian-peng</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Department of General Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Fatima Martel</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>7</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>2020</volume><elocation-id>2824984</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2019</year></date><date date-type="rev-recd"><day>7</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Zhong-Shi Hong et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p> Tenacissoside H (TDH) is a Chinese medicine monomer extracted from <italic>Marsdenia tenacissima</italic> extract (MTE), which has been confirmed to have antitumor effects, but its mechanism is still unclear. The aim of this study was to investigate the effect and mechanism of TDH on human colon cancer LoVo cell proliferation and migration and explore the correlation of TDH treatment with the expression of <italic>GOLPH3</italic> and cell signaling pathways in LoVo cells. </p></sec><sec><title>Methods</title><p> LoVo cells were treated with TDH at 0.1, 1, 10, and 100&#x02009;<italic>&#x003bc;</italic>g/mL for 24, 48, and 72&#x02009;h. The proliferation rate of LoVo cells was evaluated by MTT assay. Recombinant plasmid p-CMV-2-GOLPH3 was constructed, and p-CMV-2-GOLPH3 and p-CMV-2 empty plasmids were transfected into LoVo cells by lipofection. Western blotting was used to detect the transfection efficiency and the expression of p-p70S6K, p70S6K, <italic>&#x003b2;</italic>-catenin, and GOLPH3. The apoptosis rate was analyzed with Annexin V-FITC/PI double-staining method, and cell migration assessed by transwell assay. </p></sec><sec><title>Results</title><p> TDH inhibited the proliferation of LoVo cells in a concentration-dependent manner. The IC50 of TDH treatment in LoVo cells at 24, 48, and 72&#x02009;h was 40.24, 13.00, and 5.73&#x02009;<italic>&#x003bc;</italic>g/mL, respectively. TDH treatment significantly induced apoptosis and suppressed the viability and migration of human colon cancer LoVo cells. The effect of TDH on induction of apoptosis and inhibition of migration in LoVo cells decreased significantly after activating the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways with agonists. Additionally, the expression of GOLPH3 protein downregulated significantly in LoVo cells under TDH treatment. Overexpression of the GOLPH3 gene increased the expression of key proteins in PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways and blocked the antitumor activity of TDH. </p></sec><sec><title>Conclusion</title><p> Collectively, the present results indicated that TDH can inhibit the proliferation vitality of colon cancer LoVo cells through downregulating GOLPH3 expression and activity of PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways.</p></sec></abstract><funding-group><award-group><funding-source>Traditional Chinese Medicine Research Project of Fujian Province</funding-source><award-id>2017FJZYLC403</award-id></award-group><award-group><funding-source>Medical Innovation Project of Fujian Province</funding-source><award-id>2017-CXB-7</award-id></award-group><award-group><funding-source>The Science and Technology Project of Quanzhou</funding-source><award-id>2017Z015</award-id></award-group><award-group><funding-source>Educational Research Project for Young and Middle-Aged Teachers of Fujian Educational Committee</funding-source><award-id>JAT190216</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Colon cancer is one of the most common malignant tumors of the digestive tract. The incidence and mortality rate keep increasing worldwide [<xref rid="B1" ref-type="bibr">1</xref>]. Surgical resection is the most important means of treatment at present. However, patients in the advanced stage often received chemotherapy and targeted therapy according to individual conditions. In China, traditional Chinese medicine also plays an important role in the adjuvant treatment of malignant tumors. Studies have shown that many Chinese herbal extracts can inhibit tumor growth and improve quality of life [<xref rid="B2" ref-type="bibr">2</xref>]. Through chemical composition analysis and pharmacological studies, it was found that the extract contains different effective chemical ingredients, and the molecular mechanism of its anticancer effect is necessary for further research.</p><p>
<italic>Marsdenia tenacissima</italic> is the dry vine, root, or leaf of the genus <italic>M. tenacissima</italic> (Roxb.) Wight et Arn, and the isolated <italic>M. tenacissima</italic> extract (MTE) causes obvious inhibitory effect on various malignant cells [<xref rid="B3" ref-type="bibr">3</xref>]. Tenacissoside is a kind of major active ingredient in MTE; Tenacissoside H(TDH) is one of its monomers, molecular formula: C<sub>42</sub>H<sub>66</sub>O<sub>14</sub>, belonging to the C21 steroidal glycosides and is considered to be an antitumor active substance isolated from <italic>M. tenacissima</italic> [<xref rid="B4" ref-type="bibr">4</xref>]. However, the inhibitory effect and molecular mechanism of TDH on colon cancer is still unfamiliar.</p><p>
<italic>GOLPH3</italic> has been validated as an oncoprotein and its expression in colon cancer tissues was significantly increased compared to normal tissues [<xref rid="B5" ref-type="bibr">5</xref>]; GOLPH3 overexpression can upregulate activation of the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways, promote proliferation, and induce apoptosis in colon cancer cells. Meanwhile, silencing expression of the <italic>GOLPH3</italic> gene can reverse the resistance of HT29 colon cancer cells to 5-fluorouracil and cisplatin [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>].</p><p>It is unclear whether the antitumor effects of TDH are related to downregulation of <italic>GOLPH3</italic> gene expression and cellular signaling pathway. In the present study, we investigated the effect and mechanism of TDH on the proliferation, apoptosis, and migration in human colon cancer LoVo cells.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Drugs and Reagents</title><p>The Human colon cancer cell line LoVo (Shanghai Institute of Cell Science, Chinese Academy of Sciences); TDH (20&#x02009;mg/branch; batch number: 111913-201803; China Food and Drug Control Institute); RPMI1640 medium (Beijing Suolaibao Bioscience and Technology Co., Ltd.); pFLAG-CMV-2 vector (Sigma, St. Louis, MO, USA); cDNA reverse transcription kit (Invitrogen, Carlsbad, CA, USA); Lipofectamine<sup>TM</sup> 3000 transfection reagent (Invitrogen); Opti-MEM serum-free medium (Shanghai Tuoran Biotechnology Co., Ltd.); rabbit anti-human GOLPH3 polyclonal antibody (ab98023; Abcam, Cambridge, UK); phosphorylated ribosomal protein S6 kinase <italic>&#x003b2;</italic>1 (p-p70S6K) antibody (sc-377529; Santa Cruz Biotechnology, Santa Cruz, USA); p70S6K antibody (sc-8418; Santa Cruz Biotechnology); <italic>&#x003b2;</italic>-catenin antibody (sc-7199; Santa Cruz Biotechnology); horseradish peroxidase-labeled goat anti-rabbit IgG antibody (A0208; Beyotime, Nanking, China); WB and IP protein lysate (Shanghai Lai Maple Biotechnology Co., Ltd.); trypsin powder, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), propidium iodide (PI) staining solution, and fetal bovine serum (FBS) (Sigma); Annexin-V detection kit (Becton Dickinson, Franklin Lakes, NJ, USA); BCA Protein Quantification Kit (Shanghai Weijin Biotechnology Co., Ltd.); Luminol (Shanghai Pu Zhen Biological Technology Co., Ltd.); and tetramethylethylenediamine (TEMED; Beijing BioDee BioTech Corp. Ltd.).</p></sec><sec id="sec2.2"><title>2.2. Cell Lines and Culture</title><p>The human colon cancer cell line LoVo was purchased from Shanghai Institute of Cell Science, Chinese Academy of Sciences. The LoVo cell line was cultured in RPMI 1640&#x02009;+&#x02009;10% FBS and placed in an incubator at 37&#x000b0;C in 5% CO<sub>2</sub>&#x02009;+&#x02009;95% air in a saturated humidity environment.</p></sec><sec id="sec2.3"><title>2.3. Construction of GOLPH3 Overexpression Plasmid and Cell Transfection</title><p>Construction and identification of recombinant plasmid: total RNA in LoVo cells was extracted and reverse transcribed to obtain cDNA, which was subjected to polymerase chain reaction (PCR) amplification (underlined as an enzyme cleavage site) using the following primers: forward, TTTAAGCTTATGACCTCGCTGACCCAGC; reverse, TTTTCTAGATTACTTGGTGAACGCCGCC. The PCR amplification product was a full-length cDNA of 897 bp <italic>GOLPH3</italic> full-length cDNA (NM_022130). The PCR product was digested with <italic>Hin</italic>dIII and <italic>Xba</italic>I and ligated into the pFlag-CMV-2 vector after double digestion. The clones were selected and verified by sequencing to obtain the <italic>GOLPH3</italic> overexpression vector.</p><p>Lipofectamine transfection: (1) cells were digested in the exponential phase 1 day before transfection and plated on six-well plates at 10<sup>5</sup>/well; cells were suitable for transfection when they reached 80% confluence; (2) lipofectamine 3000 liposomes were diluted in Opti-MEM and mixed well; (3) empty vector plasmid and recombinant plasmid were diluted with Opti-MEM medium; the premix was prepared and then added with the P3000&#x02122; reagent in the kit and mixed well; (4) lipofectamine 3000 liposome was added in a ratio of 1&#x02009;:&#x02009;1 with empty vector plasmid and recombinant plasmid premix and was incubated for 5&#x02009;min at room temperature; and (5) empty plasmid-liposome complexes and recombinant plasmid-liposome complexes were added to the cell culture, and experimental tests were performed.</p></sec><sec id="sec2.4"><title>2.4. MTT Assay to Evaluate the Proliferation of LoVo Cells</title><p>After blood cell counting, LoVo cells (2&#x02009;&#x000d7;&#x02009;10<sup>3</sup>) were inoculated onto 96-well plates at 100&#x02009;<italic>&#x003bc;</italic>L/well. After 24&#x02009;h, different concentrations of TDH were added. At 24, 48, and 72&#x02009;h after drug treatment, 10&#x02009;<italic>&#x003bc;</italic>L 5&#x02009;mg/mL MTT solution was added to each well and reacted at 37&#x000b0;C for 4&#x02009;h. Each well added with DMSO and OD490 was determined by using a microplate reader. IC50 was calculated using the Logit method via comparing the OD490 values at different time points.</p></sec><sec id="sec2.5"><title>2.5. Cell Grouping</title><p>The cells were divided into the following groups: (1) Control, LoVo cells; (2) TDH&#x02009;:&#x02009;TDH-treated LoVo cells; (3) Experimental Group 1, LoVo cells treated with TDH and PI3K/AKT/mTOR signaling pathway agonist insulin-like growth factor (IGF)-1; (4) Experimental Group 2, LoVo cells treated with TDH and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway agonist Wnt agonist 1; (5) p-CMV-2&#x02009;:&#x02009;LoVo cells transfected with p-CMV-2 empty plasmid; (6) GOLPH3&#x02009;:&#x02009;LoVo cells transfected with p-CMV-2-GOLPH3 recombinant plasmid; (7) Experimental Group 3, TDH-treated LoVo cells transfected with empty plasmid; (8) Experimental Group 4: TDH-treated LoVo cells overexpressing GOLPH3 recombinant plasmid. Recombinant plasmid p-CMV-2-GOLPH3 was constructed, and p-CMV-2-GOLPH3 and p-CMV-2 empty plasmids were transfected into human colon cancer LoVo cells by lipofection.</p></sec><sec id="sec2.6"><title>2.6. Annexin V-FITC/PI Double-Staining Method to Detect Apoptosis Rate</title><p>LoVo cells were digested and seeded in six-well plates (5&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells). After 24&#x02009;h, cells were treated with different concentrations of drug according to the experimental group. The treated cells were aspirated in a suitable centrifuge tube, washed once with phosphate-buffered saline (PBS), and the appropriate amount of trypsin cell digest was added. Trypsin-EDTA solution was removed when the adherent cells were obtained. We avoided excessive trypsin digestion. The cell culture solution collected in the abovementioned step was added, mixed, transferred to a centrifuge tube, and centrifuged at 1000&#x02009;&#x000d7;<italic>g</italic> for 5&#x02009;min. The supernatant was discarded and the cells were collected and gently resuspended in PBS and counted. Resuspended cells (50,000&#x02013;100,000) were centrifuged at 1, 000&#x02009;&#x000d7;<italic>g</italic> for 5&#x02009;min, the supernatant was discarded, and cells were gently resuspended by adding 195&#x02009;<italic>&#x003bc;</italic>L Annexin V-fluorescein isothiocyanate (FITC) binding solution. We added 5&#x02009;<italic>&#x003bc;</italic>L Annexin V-FITC and mixed gently. We then added 10&#x02009;<italic>&#x003bc;</italic>L of propidium iodide (PI) stain and mixed gently. The cells were incubated at room temperature (20&#x000b0;C&#x02013;25&#x000b0;C) for 10&#x02013;20&#x02009;min in the dark and placed in an ice bath. Aluminum foil was used to protect the cells from light. The cells were resuspended two or three times during the incubation to improve the staining effect. Flow cytometry was performed immediately, Annexin V-FITC showed green fluorescence, and PI was red fluorescence.</p></sec><sec id="sec2.7"><title>2.7. Transwell Assay for Cell Migration</title><p>The LoVo cells were cultured to logarithmic growth and digested, washed, and suspended in serum-free medium, and the concentration was adjusted to 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells; in the lower chamber (i.e., the bottom of the 24-well plate), 600&#x02013;800&#x02009;<italic>&#x003bc;</italic>L culture medium containing 10% serum was added, 100&#x02009;<italic>&#x003bc;</italic>L of cell suspension was added to the upper chamber, and different drug treatments were performed according to the experimental group. After continuing culture for 24&#x02009;h, the chamber was carefully removed with forceps; the upper chamber liquid was blotted and transferred to the well and added with 800&#x02009;<italic>&#x003bc;</italic>L methanol, fixed at room temperature for 30&#x02009;min, rinsed with PBS, and soaked three times. The chamber was then taken out, the upper chamber liquid was removed, and the cells on the surface membrane of the upper chamber bottom with a wet cotton swab were transferred to the lower chamber containing 500&#x02009;<italic>&#x003bc;</italic>L of crystal violet and stained at room temperature for 30&#x02009;min; The cells were observed under an inverted microscope, photographed, and counted.</p></sec><sec id="sec2.8"><title>2.8. Western Blotting for Protein Expression</title><p>Cells in the logarithmic growth phase were collected and washed once with PBS, lysed in RIPA lysis buffer, and kept on ice for 20&#x02009;min. The protein concentration was determined by the BCA method, and the total protein of cells extracted by cell lysis was used for SDS-PAGE. After electrophoresis, proteins were transferred to nitrocellulose membranes. PBST containing 5% skimmed milk powder was sealed at room temperature for 60&#x02009;min. The blots were incubated with rabbit anti-human GOLPH3 polyclonal antibody &#x0ff08;1&#x0ff1a;1000&#x0ff09;, p-p70S6K antibody &#x0ff08;1&#x0ff1a;1000&#x0ff09;, p70S6K antibody &#x0ff08;1&#x0ff1a;1000&#x0ff09;, and <italic>&#x003b2;</italic>-catenin antibody&#x0ff08;1&#x0ff1a;1000&#x0ff09; at 4&#x000b0;C overnight and rinsed three times with PBST for 20&#x02009;min. The corresponding horseradish peroxidase-labeled secondary antibodies were added and incubated for 1&#x02009;h at room temperature and rinsed three times with PBST for 10&#x02009;min and detected with ECL chemiluminescence reagent. The image was subjected to gray-scale analysis using Image-J version 1.48 (National Institutes of Health, Bethesda, MD, USA), and the relative intensity of target protein expression is equal to the ratio of the gray value of the target protein band to the gray value of the GADPH band.</p></sec><sec id="sec2.9"><title>2.9. Statistical Analysis</title><p>Statistical analysis was performed using SPSS version 20.0. All samples were tested to ascertain if they followed the homogeneity of variance. The paired <italic>t</italic>-test was used for comparison between two groups and one-way analysis of variance was used for comparison between &#x02265;3 groups. The least significant difference method was used for multiple comparisons between groups, and <italic>P</italic> &#x0003c;0.05 indicated that the difference was statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. TDH Inhibits the Proliferation of LoVo Cells</title><p>MTT assay was used to detect the LoVo cell proliferation under TDH treatment at concentrations of 0.1, 1, 10, and 100&#x02009;<italic>&#x003bc;</italic>g/ml for 24, 48, and 72&#x02009;h, and the respective growth inhibition curves were drawn (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The results showed TDH inhibited significantly LoVo cell proliferation in a concentration-dependent manner (<xref rid="tab1" ref-type="table">Table 1</xref>). However, under the same TDH concentration, there was no significant difference in the inhibitory effect of TDH on LoVo cell proliferation as the treatment time was prolonged (<italic>P</italic> &#x0003e; 0.05). It suggested that there was no obvious time-dependent effect of TDH. The IC50 of TDH treatment in LoVo cells at 24, 48, and 72&#x02009;h was 40.24, 13.00, and 5.73&#x02009;<italic>&#x003bc;</italic>g/ml, respectively. In the subsequent experiments, the concentration of TDH was selected to be 25&#x02009;<italic>&#x003bc;</italic>g/ml.</p></sec><sec id="sec3.2"><title>3.2. TDH Induces Apoptosis of LoVo Cells</title><p>Apoptosis was detected by Annexin V-FITC/PI flow cytometry. The apoptosis rates of the Control Group, the TDH Group, Experimental Group 1, and Experimental Group 2 were 0.51&#x02009;&#x000b1;&#x02009;0.54%, 31.77&#x02009;&#x000b1;&#x02009;3.47%, 1.47&#x02009;&#x000b1;&#x02009;0.97%, and 2.68&#x02009;&#x000b1;&#x02009;1.79%, respectively. The apoptosis rate of the TDH Group was significantly higher than the Control Group (<italic>P</italic> &#x0003c; 0.01). The apoptosis rate of Experimental Group 1 and Experimental Group 2 was significantly lower than the TDH Group (<italic>P</italic> &#x0003c; 0.05) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). This result indicated that the PI3K/AKT/mTOR or Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway agonist could attenuate the apoptosis induced by TDH in LoVo cells.</p></sec><sec id="sec3.3"><title>3.3. TDH Inhibits LoVo Cell Migration</title><p>The numbers of cell migration in the Control Group, the TDH Group, Experimental Group 1, and Experimental Group 2 were 293&#x02009;&#x000b1;&#x02009;64, 47&#x02009;&#x000b1;&#x02009;12, 277&#x02009;&#x000b1;&#x02009;23, and 253&#x02009;&#x000b1;&#x02009;35, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The migrated cells in the TDH Group were significantly decreased than the Control Group (<italic>P</italic> &#x0003c; 0.05). Meanwhile, compared with the TDH Group, the migrated cells in Experimental Group 1 and Experimental Group 2 increased significantly (<italic>P</italic> &#x0003c; 0.05). The experiments showed that signal pathway agonists could reduce the inhibitory effect of TDH on migration in LoVo cells.</p></sec><sec id="sec3.4"><title>3.4. TDH Affects LoVo Cell Signaling Pathway-Related Protein Expression</title><p>Compared with the Control Group, expression of p-p70S6K and <italic>&#x003b2;</italic>-catenin in the TDH Group was significantly decreased (<italic>P</italic> &#x0003c; 0.05), and the corresponding signaling pathway was inhibited (<xref rid="tab2" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>). After adding the signaling pathway agonist (IGF-1 or Wnt agonist 1), expression of p-p70S6K in Experimental Group 1 and <italic>&#x003b2;</italic>-catenin expression in Experimental Group 2 were significantly higher than in the TDH Group (<italic>P</italic> &#x0003c; 0.05). Moreover, under TDH treatment, the GOLPH3 expression in LoVo cells was also altered, and the expression of GOLPH3 protein in the TDH Group was significantly lower than in the Control Group (<italic>P</italic> &#x0003c; 0.01). These results demonstrated that TDH could downregulate both GOLPH3 expression and activation of the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway in LoVo cells.</p></sec><sec id="sec3.5"><title>3.5. Effect of TDH on the Expression of Signaling Pathway-Related Proteins in LoVo Cells Overexpressed GOLPH3</title><p>Compared with the p-CMV-2 Group, expression of GOLPH3 protein in the GOLPH3 Group increased significantly (<italic>P</italic> &#x0003c; 0.05); it indicated that the transfection efficiency was good (<xref rid="tab3" ref-type="table">Table 3</xref>, <xref ref-type="fig" rid="fig5">Figure 5</xref>). Moreover, expression of p-p70S6K, <italic>&#x003b2;</italic>-catenin, and GOLPH3 proteins in Experimental Group 4 was increased significantly than Experimental Group 3 (<italic>P</italic> &#x0003c; 0.05). It implied that GOLPH3 overexpression can hinder the inhibitory effect of TDH on PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways in LoVo cells.</p></sec><sec id="sec3.6"><title>3.6. Effect of TDH on Apoptosis in LoVo Cells Overexpressed GOLPH3</title><p>Apoptosis was detected by Annexin V&#x02013;FITC/PI flow cytometry. Apoptosis rates in the p-CMV-2 Group, the GOLPH3 Group, Experimental Group 3, and Experimental Group 4 were 1.11&#x02009;&#x000b1;&#x02009;0.65%, 0.34&#x02009;&#x000b1;&#x02009;0.35%, 30.06&#x02009;&#x000b1;&#x02009;4.86%, and 2.27&#x02009;&#x000b1;&#x02009;1.19% (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The apoptosis rate of Experimental Group 3 was significantly higher than the p-CMV-2 Group, while the apoptosis rate of Experimental Group 4 was significantly lower than Experimental Group 3 (<italic>P</italic> &#x0003c; 0.01). This result testified that GOLPH3 overexpression in LoVo cells could arrest the TDH-induced apoptosis.</p></sec><sec id="sec3.7"><title>3.7. Effect of TDH on Migration in LoVo Cells Overexpressed GOLPH3</title><p>The numbers of cell migration in the p-CMV-2 Group, the GOLPH3 Group, Experimental Group 3, and Experimental Group 4 were 301&#x02009;&#x000b1;&#x02009;26, 372&#x02009;&#x000b1;&#x02009;55, 39&#x02009;&#x000b1;&#x02009;14, and 284&#x02009;&#x000b1;&#x02009;31, respectively(<xref ref-type="fig" rid="fig7">Figure 7</xref>). The number of migrated cells in Experiment Group 3 was significantly decreased than the p-CMV-2 Group (<italic>P</italic> &#x0003c; 0.01). Correspondingly, the number of migrated cells in Experimental Group 4 was also significantly higher than that in Experimental Group 3 (<italic>P</italic> &#x0003c; 0.01). The experiments manifested that the inhibitory effect of TDH on migration in LoVo cells overexpressed GOLPH3 significantly weakened.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>In China, the incidence and mortality of colorectal cancer continue to rise [<xref rid="B9" ref-type="bibr">9</xref>]. Although chemotherapy and targeted drugs can improve the survival rate, they are expensive and have obvious adverse effects. To improve the life quality of patients with advanced colon cancer by comprehensive treatment, traditional Chinese medicine is used to assist patients with colon cancer. It can effectively reduce the adverse effects of chemotherapy, improve immunity, and play an important role in the treatment of colon cancer [<xref rid="B10" ref-type="bibr">10</xref>]. <italic>M. tenacissima</italic> is widely used as a traditional Chinese medicine in clinical practice; its preparation Xiaoaiping is used for adjuvant treatment in various malignant tumors; it was interesting to note that the therapeutic effect is remarkable and the adverse reactions are few [<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>]. The composition of <italic>M. tenacissima</italic> is complex, and its antitumor mechanism is still unclear and needs further study.</p><p>Related studies have shown that TDH can inhibit the proliferation of esophageal cancer cells by regulating the cell cycle and reducing proliferating cell nuclear antigen expression [<xref rid="B14" ref-type="bibr">14</xref>]. TDH can also inhibit the growth of mouse lung cancer cells, reduce the number of lung metastases, and enhance the immune function of tumor-bearing mice by regulating Th1/Th2-related cytokines [<xref rid="B15" ref-type="bibr">15</xref>]. We found that TDH had a significant concentration-dependent inhibitory effect on the proliferation of human colon cancer LoVo cells <italic>in vitro</italic>; moreover, it can also induce apoptosis and inhibit the migration of LoVo cells; these results indicated that TDH could inhibit colon cancer cell viability and metastasis. The abnormal activation of the PI3K/AKT/mTOR signaling pathway has been observed in a variety of human tumors, including esophageal, ovarian, breast, and colorectal cancer and promoted the development of tumor by promoting cell proliferation, inhibiting apoptosis, or activating angiogenesis [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>]. The aberrant activation of the Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway has been also demonstrated in colorectal cancer and regulates gene expression and cell invasion, migration, proliferation, and differentiation in the initiation and progression of CRC [<xref rid="B20" ref-type="bibr">20</xref>]. In the present study, under TDH treatment, the expression of p-p70S6K and <italic>&#x003b2;</italic>-catenin was significantly reduced in LoVo cells; however, the expression of p-p70S6K and <italic>&#x003b2;</italic>-catenin was upregulated, apoptosis decreased, and cell migration increased after using mTOR and Wnt signaling pathway agonists; the result suggested that TDH may exert antitumor activity through inhibiting the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways in the colon cancer.</p><p>In addition, we also found that the decrease of GOLPH3 expression was detected in LoVo cells under TDH treatment. GOLPH3 is localized in the Golgi apparatus, widely involved in many important physiological processes, and plays an important role in glycosyltransferases location, glycosylation, and secretory trafficking which were related to cancer development. <italic>GOLPH3</italic> is a oncogene that is frequently overexpressed in various malignant tumor tissues, including glioma and liver, lung, ovarian, and esophageal cancer, and is positively correlated with poor prognosis [<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>]. It is also reported that GOLPH3 overexpression can activate various signaling pathways, promote cell proliferation, inhibit apoptosis, and induce the sensitivity of colon cancer cells to cisplatin and 5-FU [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. In the present study, under the same condition of TDH treatment, compared with nontransfected LoVo cells, p-p70S6K and <italic>&#x003b2;</italic>-catenin expression and cell migration increased in LoVo cells overexpressed <italic>GOLPH3</italic>; these results suggested that the antitumor effect of TDH on LoVo cells was related to inhibition of the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways through downregulating <italic>GOLPH3</italic> gene expression. Therefore, we can reasonably speculate that TDH can block the resistance of colon cancer cells to cisplatin and 5-FU and improve chemotherapeutic efficacy in patients with advanced colon cancer.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>TDH can inhibit the proliferation and migration and induce apoptosis in human colon cancer LoVo cells. The mechanism is that TDH can inhibit the PI3K/AKT/mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signaling pathways by downregulating <italic>GOLPH3</italic> gene expression.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely thank Yanta Guo from the Second Affiliated Hospital of Fujian Medical University (Quanzhou, Fujian, China), Mingzhen Wang from Xiamen Hospital of TCM (Xiamen, Fujian, China), and Zhixiong Chen from the Fifth Hospital of Xiamen (Xiamen, Fujian, China) for providing experimental suggestions. This research was supported by the Traditional Chinese Medicine Research Project of Fujian Province (Grant no. 2017FJZYLC403), the Medical Innovation Project of Fujian Province (Grant no. 2017-CXB-7), the Science and Technology Project of Quanzhou (Grant no. 2017Z015), and the Educational Research Project for Young and Middle-Aged Teachers of Fujian Educational Committee (Grant no. JAT190216).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Torre</surname><given-names>L. A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source><italic toggle="yes">CA: A Cancer Journal for Clinicians</italic></source><year>2018</year><volume>68</volume><issue>6</issue><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="other">2-s2.0-85053395052</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Lai</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>Anticancer properties of traditional Chinese medicine</article-title><source><italic toggle="yes">Comb Chem High Throughput Screen</italic></source><year>2017</year><volume>20</volume><issue>5</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.2174/1386207320666170116141818</pub-id><pub-id pub-id-type="other">2-s2.0-85031496463</pub-id><pub-id pub-id-type="pmid">28093974</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The antitumor activities of Marsdenia tenacissima</article-title><source><italic toggle="yes">Front Oncology</italic></source><year>2018</year><volume>8</volume><fpage>p. 473</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00473</pub-id><pub-id pub-id-type="other">2-s2.0-85063267147</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>L.-Y.</given-names></name><name><surname>Ren</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Metabolic profiling of tenacigenin B, tenacissoside H and tenacissoside I using UHPLC-ESI-Orbitrap MS/MS</article-title><source><italic toggle="yes">Biomedical Chromatography</italic></source><year>2016</year><volume>30</volume><issue>11</issue><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1002/bmc.3750</pub-id><pub-id pub-id-type="other">2-s2.0-84991212217</pub-id><pub-id pub-id-type="pmid">27106066</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.-T.</given-names></name><name><surname>Qiu</surname><given-names>C. Z.</given-names></name><name><surname>Huang</surname><given-names>Z. X.</given-names></name><name><surname>Yu</surname><given-names>W. S.</given-names></name><name><surname>Yang</surname><given-names>X. F.</given-names></name><name><surname>Wang</surname><given-names>M. Z.</given-names></name></person-group><article-title>Correlational research of Golgi phosphorylation protein 3 expression in colorectal cancer</article-title><source><italic toggle="yes">World Journal of Gastroenterology</italic></source><year>2015</year><volume>21</volume><issue>48</issue><fpage>13473</fpage><lpage>13479</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i48.13473</pub-id><pub-id pub-id-type="other">2-s2.0-84953235823</pub-id><pub-id pub-id-type="pmid">26730158</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>C.-Z.</given-names></name><name><surname>Wang</surname><given-names>M.-Z.</given-names></name><name><surname>Yu</surname><given-names>W.-S.</given-names></name><name><surname>Guo</surname><given-names>Y.-T.</given-names></name><name><surname>Wang</surname><given-names>C.-X.</given-names></name><name><surname>Yang</surname><given-names>X.-F.</given-names></name></person-group><article-title>Correlation of GOLPH3 gene with Wnt signaling pathway in human colon cancer cells</article-title><source><italic toggle="yes">Journal of Cancer</italic></source><year>2016</year><volume>7</volume><issue>8</issue><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.7150/jca.13968</pub-id><pub-id pub-id-type="other">2-s2.0-84980015809</pub-id><pub-id pub-id-type="pmid">27313783</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M. Z.</given-names></name><name><surname>Qiu</surname><given-names>C. Z.</given-names></name><name><surname>Yu</surname><given-names>W. S.</given-names></name><name><surname>Guo</surname><given-names>Y. T.</given-names></name><name><surname>Wang</surname><given-names>C. X.</given-names></name><name><surname>Chen</surname><given-names>Z. X.</given-names></name></person-group><article-title>GOLPH3 expression promotes the resistance of HT29 cells to 5-fluorouracil by activating multiple signaling pathways</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>542</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">29115442</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z. P.</given-names></name><name><surname>Wang</surname><given-names>L. P.</given-names></name><name><surname>Hong</surname><given-names>Z. S.</given-names></name><etal/></person-group><article-title>Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways</article-title><source><italic toggle="yes">International Journal of Oncology</italic></source><year>2018</year><volume>53</volume><issue>3</issue><fpage>1183</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">30015866</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><article-title>Hospital authority of national Health and family planning commission of the People&#x02032;s Republic of China and Chinese society of oncology., &#x0201c;Chinese protocol of diagnosis and treatment of colorectal cancer</article-title><source><italic toggle="yes">Zhonghua Wai Ke Za Zhi</italic></source><year>2018</year><volume>56</volume><issue>4</issue><fpage>241</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">29562407</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name></person-group><article-title>Bulibu jillishan and kebinu mijiti, &#x0201c;application of traditional Chinese medicine in the adjuvant treatment of colon cancer</article-title><source><italic toggle="yes">Chinese Pharmacist</italic></source><year>2018</year><volume>21</volume><issue>9</issue><fpage>133</fpage><lpage>136</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The Chinese herb Xiaoaiping protects against breast cancer chemotherapy-induced alopecia and other side effects: a randomized controlled trial</article-title><source><italic toggle="yes">Journal of International Medical Research</italic></source><year>2019</year><volume>47</volume><issue>6</issue><fpage>2607</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.1177/0300060519842781</pub-id><pub-id pub-id-type="other">2-s2.0-85067180318</pub-id><pub-id pub-id-type="pmid">31099281</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>A.-W.</given-names></name><name><surname>Chen</surname><given-names>Y.-Q.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.-L.</given-names></name><name><surname>Jia</surname><given-names>D.-D.</given-names></name></person-group><article-title>Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines</article-title><source><italic toggle="yes">Biomedicine &#x00026; Pharmacotherapy</italic></source><year>2017</year><volume>89</volume><fpage>1172</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.03.012</pub-id><pub-id pub-id-type="other">2-s2.0-85015703545</pub-id><pub-id pub-id-type="pmid">28320083</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>Q. X.</given-names></name><name><surname>Wang</surname><given-names>H. H.</given-names></name><name><surname>Han</surname><given-names>D. M.</given-names></name><name><surname>Song</surname><given-names>N. S.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group><article-title>Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer</article-title><source><italic toggle="yes">Zhonghua Zhong Liu Za Zhi</italic></source><year>2017</year><volume>39</volume><issue>6</issue><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">28635236</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y. S.</given-names></name><name><surname>Hu</surname><given-names>X. Q.</given-names></name><name><surname>Gabriella</surname><given-names>H.</given-names></name><name><surname>Qin</surname><given-names>L. J.</given-names></name><name><surname>Meggyeshazi</surname><given-names>N.</given-names></name></person-group><article-title>Antitumor activity of tenacissoside H on esophageal cancer through arresting cell cycle and regulating PI3K/Akt-NF-<italic>&#x003ba;</italic>B transduction cascade</article-title><source><italic toggle="yes">Evid Based Complement Alternative Medicine</italic></source><year>2015</year><volume>2015</volume><pub-id pub-id-type="publisher-id">464937</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W. J.</given-names></name><name><surname>Zhang</surname><given-names>G. Q.</given-names></name><name><surname>Liu</surname><given-names>S. J.</given-names></name><name><surname>Liu</surname><given-names>T. X.</given-names></name></person-group><article-title>Anti-tumor effect of tenacissoside H and influence on immune function of lewis lung cancer mice</article-title><source><italic toggle="yes">Chinese Journal of Traditional Chinese Medicine</italic></source><year>2014</year><volume>21</volume><issue>4</issue><fpage>63</fpage><lpage>66</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma</article-title><source><italic toggle="yes">OncoTargets and Therapy</italic></source><year>2019</year><volume>12</volume><fpage>5215</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.2147/ott.s207238</pub-id><pub-id pub-id-type="other">2-s2.0-85071081763</pub-id><pub-id pub-id-type="pmid">31308693</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression</article-title><source><italic toggle="yes">BMC Cancer</italic></source><year>2019</year><volume>19</volume><issue>1</issue><fpage>p. 618</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5824-9</pub-id><pub-id pub-id-type="other">2-s2.0-85068143649</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P.-W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Gu</surname><given-names>Y.-T.</given-names></name></person-group><article-title>Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway</article-title><source><italic toggle="yes">Journal of Cellular Physiology</italic></source><year>2019</year><volume>234</volume><issue>2</issue><fpage>1904</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.1002/jcp.27066</pub-id><pub-id pub-id-type="other">2-s2.0-85052480725</pub-id><pub-id pub-id-type="pmid">30145819</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway</article-title><source><italic toggle="yes">Cancer Letters</italic></source><year>2018</year><volume>436</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.08.012</pub-id><pub-id pub-id-type="other">2-s2.0-85052479761</pub-id><pub-id pub-id-type="pmid">30118845</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Therapeutic potential of targeting the Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway in colorectal cancer</article-title><source><italic toggle="yes">Biomedicine &#x00026; Pharmacotherapy</italic></source><year>2019</year><volume>110</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.082</pub-id><pub-id pub-id-type="other">2-s2.0-85057852489</pub-id><pub-id pub-id-type="pmid">30530050</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor</article-title><source><italic toggle="yes">Neuro-Oncology</italic></source><year>2017</year><volume>19</volume><issue>12</issue><fpage>1628</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nox104</pub-id><pub-id pub-id-type="other">2-s2.0-85040049677</pub-id><pub-id pub-id-type="pmid">28575494</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway</article-title><source><italic toggle="yes">BMC Cancer</italic></source><year>2018</year><volume>18</volume><issue>1</issue><fpage>p. 661</fpage><pub-id pub-id-type="doi">10.1186/s12885-018-4458-7</pub-id><pub-id pub-id-type="other">2-s2.0-85048706756</pub-id><pub-id pub-id-type="pmid">29914442</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Expression of GOLPH3 in patients with non-small cell lung cancer and xenografts models</article-title><source><italic toggle="yes">Oncology Letters</italic></source><year>2018</year><volume>15</volume><issue>15</issue><fpage>7555</fpage><lpage>7562</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8340</pub-id><pub-id pub-id-type="other">2-s2.0-85044643024</pub-id><pub-id pub-id-type="pmid">29849795</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>GOLPH3 induces epithelial-mesenchymal transition via Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway in epithelial ovarian cancer</article-title><source><italic toggle="yes">Cancer Medicine</italic></source><year>2017</year><volume>6</volume><issue>4</issue><fpage>834</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1002/cam4.1040</pub-id><pub-id pub-id-type="other">2-s2.0-85016406244</pub-id><pub-id pub-id-type="pmid">28332316</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.-H.</given-names></name><name><surname>Yuan</surname><given-names>L.-J.</given-names></name><name><surname>Liang</surname><given-names>R.-X.</given-names></name><etal/></person-group><article-title>GOLPH3 promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma via mTOR and Wnt/<italic>&#x003b2;</italic>-catenin signal activation</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2017</year><volume>16</volume><issue>5</issue><fpage>7138</fpage><lpage>7144</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.7495</pub-id><pub-id pub-id-type="other">2-s2.0-85030087815</pub-id><pub-id pub-id-type="pmid">28901498</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Inhibition of LoVo cells proliferation under different concentrations of TDH treatment. The IC50 of TDH in LoVo cells at 24, 48, and 72&#x02009;h was 40.24, 13.00, and 5.73&#x02009;<italic>&#x003bc;</italic>g/ml.</p></caption><graphic xlink:href="ECAM2020-2824984.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Apoptosis rate of LoVo cells under TDH treatment. Comparison of the TDH Group with the Control Group (<sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01). Comparisons of Experimental Group 1 and Experimental Group 2 with the TDH Group (<sup>#</sup><italic>P</italic> &#x0003c; 0.01, <sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ECAM2020-2824984.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>LoVo cell migration under TDH treatment. Comparison of the TDH Group with the Control Group (<sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05). Comparisons of Experimental Group 1 and Experimental Group 2 with the TDH Group (<sup>#</sup><italic>P</italic> &#x0003c; 0.05, <sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ECAM2020-2824984.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>(a) Expression of related proteins in LoVo cells under TDH treatment. (b) The TDH Group compared with the Control Group (<sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001); (c) Experimental Group 1 and (d) Experimental Group 2 compared with the TDH Group (NS <italic>P</italic> &#x0003c; 0.05, <sup>#</sup><italic>P</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="ECAM2020-2824984.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>(a) Expression of related proteins in LoVo cells overexpressed GOLPH3 under TDH treatment. (b) The GOLPH3 Group and (c) Experimental Group 3 compared with the p-CMV-2 Group (<sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01); (d) Experimental Group 4 compared with Experimental Group 3 (<sup>#</sup><italic>P</italic> &#x0003c; 0.05, <sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ECAM2020-2824984.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Apoptosis rate of LoVo cells overexpressed GOLPH3 under TDH treatment. Experimental Group 3 compared with the p-CMV-2 Group (<sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01); Experimental Group 4 compared with Experimental Group 3 (<sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ECAM2020-2824984.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Effect of TDH on migration in LoVo cells overexpressed GOLPH3 under TDH treatment. Experimental Group 3 compared with the p-CMV-2 Group (<sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01); Experimental Group 4 compared with Experimental Group 3 (<sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ECAM2020-2824984.007"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Proliferation inhibition rates of LoVo cells under TDH treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">TDH concentration</th><th align="center" colspan="3" rowspan="1">Proliferation inhibition rate (%)</th></tr><tr><th align="left" rowspan="1" colspan="1">(<italic>&#x003bc;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">24&#x02009;h</th><th align="center" rowspan="1" colspan="1">48&#x02009;h</th><th align="center" rowspan="1" colspan="1">72&#x02009;h</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.00&#x02009;&#x000b1;&#x02009;15.06</td><td align="center" rowspan="1" colspan="1">0.00&#x02009;&#x000b1;&#x02009;4.53</td><td align="center" rowspan="1" colspan="1">0.00&#x02009;&#x000b1;&#x02009;14.22</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">10.72&#x02009;&#x000b1;&#x02009;8.78 NS</td><td align="center" rowspan="1" colspan="1">14.98&#x02009;&#x000b1;&#x02009;29.49 NS</td><td align="center" rowspan="1" colspan="1">14.42&#x02009;&#x000b1;&#x02009;9.19 NS</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">16.74&#x02009;&#x000b1;&#x02009;16.20 NS</td><td align="center" rowspan="1" colspan="1">20.00&#x02009;&#x000b1;&#x02009;16.76 NS</td><td align="center" rowspan="1" colspan="1">22.96&#x02009;&#x000b1;&#x02009;12.80<sup><italic>&#x02217;&#x02217;</italic></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">30.17&#x02009;&#x000b1;&#x02009;18.43<sup><italic>&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">37.00&#x02009;&#x000b1;&#x02009;12.22<sup><italic>&#x02217;&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">50.62&#x02009;&#x000b1;&#x02009;9.88<sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">63.61&#x02009;&#x000b1;&#x02009;18.27<sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">79.81&#x02009;&#x000b1;&#x02009;11.34<sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">89.63&#x02009;&#x000b1;&#x02009;3.64<sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup></td></tr></tbody></table><table-wrap-foot><fn><p>Results are shown as mean&#x02009;&#x000b1;&#x02009;SD. Comparisons of different concentrations in the same time (NS <italic>P</italic> &#x0003e; 0.05, <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001). 24&#x02009;h, <italic>F</italic>&#x02009;=&#x02009;9.725; 48&#x02009;h, <italic>F</italic>&#x02009;=&#x02009;12.959; 72&#x02009;h, <italic>F</italic>&#x02009;=&#x02009;44.726.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Expression levels of proteins under TDH treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">p-p70S6K/p70S6K</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>-Catenin</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">1.00&#x02009;&#x000b1;&#x02009;0.10</td><td align="center" rowspan="1" colspan="1">1.00&#x02009;&#x000b1;&#x02009;0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">TDH</td><td align="center" rowspan="1" colspan="1">0.30&#x02009;&#x000b1;&#x02009;0.17<sup><italic>&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">0.12&#x02009;&#x000b1;&#x02009;0.06<sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TDH&#x02009;+&#x02009;IGF-1</td><td align="center" rowspan="1" colspan="1">0.83&#x02009;&#x000b1;&#x02009;0.18<sup>#</sup></td><td align="center" rowspan="1" colspan="1">0.80&#x02009;&#x000b1;&#x02009;0.22<sup>#</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TDH&#x02009;+&#x02009;Wnt agonist 1</td><td align="center" rowspan="1" colspan="1">0.71&#x02009;&#x000b1;&#x02009;0.15 NS</td><td align="center" rowspan="1" colspan="1">0.70&#x02009;&#x000b1;&#x02009;0.17<sup>#</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Results are shown as mean&#x02009;&#x000b1;&#x02009;SD. The TDH Group compared with the Control Group (<sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001); Experimental Group 1 and Experimental Group 2 compared with the TDH Group (NS <italic>P</italic> &#x0003e; 0.05, <sup>#</sup><italic>P</italic> &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Expression levels of proteins in LoVo cells overexpressed GOLPH3 under TDH treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">p-p70S6K/p70S6K</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>-Catenin</th><th align="center" rowspan="1" colspan="1">GOLPH3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">pCMV-control</td><td align="center" rowspan="1" colspan="1">1.00&#x02009;&#x000b1;&#x02009;0.18</td><td align="center" rowspan="1" colspan="1">1.00&#x02009;&#x000b1;&#x02009;0.11</td><td align="center" rowspan="1" colspan="1">1.00&#x02009;&#x000b1;&#x02009;0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">pCMV-GOLPH3</td><td align="center" rowspan="1" colspan="1">1.29&#x02009;&#x000b1;&#x02009;0.18<sup><italic>&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">1.63&#x02009;&#x000b1;&#x02009;0.06<sup><italic>&#x02217;&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">3.82&#x02009;&#x000b1;&#x02009;0.52<sup><italic>&#x02217;</italic></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TDH&#x02009;+&#x02009;pCMV-control</td><td align="center" rowspan="1" colspan="1">0.29&#x02009;&#x000b1;&#x02009;0.05<sup><italic>&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">0.24&#x02009;&#x000b1;&#x02009;0.07<sup><italic>&#x02217;</italic></sup></td><td align="center" rowspan="1" colspan="1">0.17&#x02009;&#x000b1;&#x02009;0.12<sup><italic>&#x02217;</italic></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TDH&#x02009;+&#x02009;pCMV-GOLPH3</td><td align="center" rowspan="1" colspan="1">1.24&#x02009;&#x000b1;&#x02009;0.17<sup>##</sup></td><td align="center" rowspan="1" colspan="1">1.82&#x02009;&#x000b1;&#x02009;0.44<sup>#</sup></td><td align="center" rowspan="1" colspan="1">3.57&#x02009;&#x000b1;&#x02009;0.55<sup>#</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Results are shown as mean&#x02009;&#x000b1;&#x02009;SD. The GOLPH3 Group and Experimental Group 3 compared with the p-CMV-2 Group (<sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01); Experimental Group 4 compared with Experimental Group 3 (<sup>#</sup><italic>P</italic> &#x0003c; 0.05, <sup>##</sup><italic>P</italic> &#x0003c; 0.01).</p></fn></table-wrap-foot></table-wrap></floats-group></article>